Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcareFRA:PBV +2.82%72 EV-to-FCF is 18.91 as of Aug. 20, 2026, which is 2% below its 10-year median of 19.22. GuruFocus rates FRA:PBV with a GF Score™ of 72/100 and a GF Value™ of €59.76 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 558 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 54.3% on this metric.
The historical rank and industry rank for Prestige Consumer Healthcare's EV-to-FCF or its related term are showing as below:
FRA:PBV'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.03 Med: 19.22 Max: 35.82
Current: 18.81
During the past 13 years, the highest EV-to-FCF of Prestige Consumer Healthcare was 35.82. The lowest was 13.03. And the median was 19.22.
FRA:PBV's EV-to-FCF is ranked better than 54.3% of 558
companies
in the Drug Manufacturers industry
Industry Median: 21.27
vs FRA:PBV: 18.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prestige Consumer Healthcare's PE Ratio (TTM) for today is calculated as:
Prestige Consumer Healthcare's share price for today is €43.80.
Prestige Consumer Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.067.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Prestige Consumer Healthcare EV-to-FCF Related Terms
Prestige Consumer Healthcare EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's EV-to-FCF falls into.
Prestige Consumer Healthcare's current Enterprise Value is €3,824.0 Mil.
Prestige Consumer Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €202.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (FRA:PBV) has a EV-to-FCF of 18.91 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prestige Consumer Healthcare and its competitors. This is near median its historical median of 19.22. Over the past decade, Prestige Consumer Healthcare's EV-to-FCF has ranged from 13.03 to 35.82. According to the industry distribution chart, Prestige Consumer Healthcare ranks #255 out of 558 companies in the Drug Manufacturers industry, placing it in the top 45.7%.
Is Prestige Consumer Healthcare's EV-to-FCF too high?
Prestige Consumer Healthcare's current EV-to-FCF of 18.91 is near median its 10-year median of 19.22. Over the past 10 years, this metric has ranged from a low of 13.03 to a high of 35.82. The Drug Manufacturers industry median EV-to-FCF is 21.27. Prestige Consumer Healthcare's value of 18.91 is 11.1% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #255 out of 558 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's EV-to-FCF compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #255 out of 558 companies for EV-to-FCF. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median EV-to-FCF is 21.27. Prestige Consumer Healthcare's value of 18.91 is 11.1% below this benchmark. Historically, Prestige Consumer Healthcare's own EV-to-FCF has ranged from 13.03 to 35.82 over the past decade. While the company's 10-year median is 19.22 vs. the industry median of 21.27, Prestige Consumer Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.27, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current EV-to-FCF of 18.91 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current EV-to-FCF is 18.91, which is near median its own 10-year median of 19.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (FRA:PBV) is currently considered Modestly Undervalued. The stock's GF Value™ is €59.76, compared to a current price of €43.80 — trading 26.7% below its estimated fair value. The current EV-to-FCF is 18.91, which is near median its 10-year median of 19.22 and 11.1% below the Drug Manufacturers industry median of 21.27. Prestige Consumer Healthcare's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Prestige Consumer Healthcare (FRA:PBV), the current EV-to-FCF is 18.91 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of €43.80 is trading 26.7% below its estimated GF Value™ of €59.76.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for FRA:PBV:
EV-to-FCF: 18.91 (near median its 10-year median of 19.22)
GF Value™: €59.76 vs. price of €43.80 (26.7% below fair value)
Industry Position: 11.1% below the Drug Manufacturers median (#255 of 558)
No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
72GF Score
Get the complete analysis for FRA:PBV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBV has been successfully added to your 
